Limited P-glycoprotein mediated efflux for anti-epileptic drugs

References

• Alsenz J, Steffen H, Alex R. Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers. Pharm Res 1998; 15: 423–428
   PubMed Web of Science ®Google Scholar
• Aronica E, Gorter JA, Jansen GH, Van Veelen CWM, Van Rijen PC, Leenstra S, Ramkema M, Scheffer GL, Scheper RJ, Troost D. Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: Focal cortical dysplasia and glioneuronal tumors. Neuroscience 2003; 118: 417–429
   PubMed Web of Science ®Google Scholar
• Artursson P. Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorbtive (Caco-2) cells. J Pharm Sci 1990; 79: 476–482
   PubMed Web of Science ®Google Scholar
• Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Del Rev 1996; 22: 67–84
   Web of Science ®Google Scholar
• Belal F, Abdine H, Al-Majed A, Khalil NY. Spectrofluorimetric determination of vigabatrin and gabapentin in urine and dosage forms through derivatization with fluorescamine. J Pharm Biomed Anal 2002; 27: 253–260
   PubMed Web of Science ®Google Scholar
• Burton P, Goodwin J, Conradi R, Ho N, Hilgers R. In vitro permeability of peptidomimetic drugs: The role of polarized efflux pathways as additional barriers to absorption. Adv Drug Del Rev 1997; 23: 143–156
   Web of Science ®Google Scholar
• Chen S, Carvey PM. Rapid approach to the quantitative determination of topiramate (2,3:4,5-bis-O-(1-methylethylidene)-beta d fructopyranose sulfamate) in human plasma by liquid–liquid extraction and flow-injection negative-ion electrospray mass spectrometry. Rapid Commun Mass Spectrom 1999; 13: 1980–1984
   PubMed Web of Science ®Google Scholar
• Crowe A. The influence of P-glycoprotein on morphine transport in Caco-2 cells. Comparison with paclitaxel. Eur J Pharmacol 2002; 440: 7–16
   PubMed Web of Science ®Google Scholar
• Crowe A, Lemaire M. In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: Comparison with rapamycin. Pharm Res 1998; 15: 1666–1672
   PubMed Web of Science ®Google Scholar
• Deckers CLP, Genton P, Sills GJ, Schmidt D. Current limitations of antiepileptic drug therapy: A conference review. Epilepsy Res 2003; 53: 1–17
   PubMed Web of Science ®Google Scholar
• Didziapetris R, Japertas P, Avdeef A, Petrauskas A. Classification analysis of P-glycoprotein substrate specificity. J Drug Target 2003; 11: 391–406
   PubMed Web of Science ®Google Scholar
• Dimitrijevic D, Whitton PS, Domin M, Welham K, Florence AT. Increased vigabatrin entry into the brain by polysorbate 80 and sodium caprate. J Pharm Pharmacol 2001; 53: 149–154
   PubMed Web of Science ®Google Scholar
• Horie K, Tang F, Borchardt R. Isolation and characterization of Caco-2 subclones expressing high levels of multidrug resistance protein efflux transporter. Pharm Res 2003; 20: 161–168
   PubMed Web of Science ®Google Scholar
• Hosoya K, Kim K, Lee V. Age-dependent expression of P-glycoprotein gp170 in Caco-2 cell monolayers. Pharm Res 1996; 13: 885–890
   PubMed Web of Science ®Google Scholar
• Ingels F, Deferme S, Destexhe E, Oth M, Van den Mooter G, Augustijns P. Simulated intestinal fluid as transport medium in the Caco-2 Cell culture model. Int J Pharm 2002; 232: 183–192
   PubMed Web of Science ®Google Scholar
• Kazuhiro K, Lee R, Xu H, Harper P, Ito S. Effects of human milk and formula on expression MDR1, MRP2 and CYP3A in the C2BBE1 intestinal cell model. Clin Pharmacol Ther 2004; 75: P51
   Web of Science ®Google Scholar
• Kwan P, Sills GJ, Butler E, Gant TW, Brodie MJ. Differential expression of multidrug resistance genes in Maive rat brain. Neurosci Lett 2003; 339: 33–36
   PubMed Web of Science ®Google Scholar
• Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: Clinical implications. Clin Pharmacokinet 2003; 42: 59–98
   PubMed Web of Science ®Google Scholar
• Luer MS, Hamani C, Dujovny M, Gidal B, Cwik M, Deyo K, Fischer JH. Saturable transport of gabepentin at the blood–brain barrier. Neurol Res 1999; 21: 559–562
   PubMed Web of Science ®Google Scholar
• Löscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J Pharmacol Exp Ther 2002; 301: 7–14
   PubMed Web of Science ®Google Scholar
• Marchi N, Hallene KL, Kight KM, Cucullo L, Moddel G, Bingaman W, Dini G, Vessani A, Janigro D. 2004. Significance of MDR1 and multiple drug resistance in refractory human epileptic brain, BMC Medicine 2: Http://www.biomedcentral.com/1741-7015/2/37
   Google Scholar
• Marroni M, Agrawal ML, Kight K, Hallene KL, Hossain M, Cucullo L, Signorelli K, Namura S, Bingaman W, Janigro D. Relationship between expression of multiple drug resistance proteins and p53 tumor suppressor gene proteins in human brain astrocytes. Neuroscience 2003; 121: 605–617
   PubMed Web of Science ®Google Scholar
• Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Pers Clin Pharm 2004; 75: 13–33
   Web of Science ®Google Scholar
• Morita Y, Sakaeda T, Horinouchi M, Nakamura T, Kuroda K, Miki I, Yoshimura K, Sakai T, Shirasaka D, Tamura T, Aoyama N, Kasuga M, Okumura K. MDR1 genotype-related duodenal absorption rate of digoxin in healthy Japanese subjects. Pharm Res 2003; 20: 552–556
   PubMed Web of Science ®Google Scholar
• Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK. Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 2001; 51: 345–349
   PubMed Web of Science ®Google Scholar
• Pauli-Magnus C, Feiner J, Brett C, Lin E, Kroetz DL. No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin Pharmacol Ther 2003; 74: 487–498
   PubMed Web of Science ®Google Scholar
• Pendse S, Briscoe DM, Frank M. P-glycoprotein and alloimmune T-cell activation. Clin App Immuno Rev 2003; 4: 3–14
   PubMedGoogle Scholar
• Potschka H, Loscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood–brain barrier of rats. Epilepsia 2001a; 42: 1231–1240
   PubMed Web of Science ®Google Scholar
• Potschka H, Loscher W. Multidrug resistance-associated protein is involved in the regulation of extracellular levels of phenytoin in the brain. Neuroreport 2001b; 12: 2387–2389
   PubMed Web of Science ®Google Scholar
• Potschka H, Fedrowitz M, Löscher W. P-glycoprotein-mediated efflux of phenobarbital, lamotrigine and felbamate at the blood–brain barrier: Evidence from micridialysis experiments in rats. Neurosci Lett 2002; 327: 173–176
   PubMed Web of Science ®Google Scholar
• Raeissi SD, Hidalgo IJ, Segura-Aguilar J, Artursson P. Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. Pharm Res 1999; 16: 625–632
   PubMed Web of Science ®Google Scholar
• Reiss WG, Oles KS. Acetazolamide in the treatment of seizures. Ann Pharmacother 1996; 30: 514–519
   PubMed Web of Science ®Google Scholar
• Rizzi M, Caccia S, Guiso G, Richichi C, Gorter JA, Aronica E, Aliprandi M, Bagnati R, Fanelli R, D'Incalci M, Samanin R, Vezzani A. Limbic seizures induce P-glycoprotein in rodent brain: Functional implications for pharmacoresistance. J Neurosci 2002; 22: 5833–5839
   PubMed Web of Science ®Google Scholar
• Sadeque AJM, Wandel C, He H, Shah S, Wood AJJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000; 68: 231–237
   PubMed Web of Science ®Google Scholar
• Schinkel AH. P-glycoprotein, a gatekeeper in the blood–brain barrier. Adv Drug Del Rev 1999; 36: 179–194
   PubMed Web of Science ®Google Scholar
• Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517–2524
   PubMed Web of Science ®Google Scholar
• Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Ann Rev Pharmacol Toxicol 2003; 43: 285–307
   PubMed Web of Science ®Google Scholar
• Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A, Goldstein DB, Wood NW, Sisodiya SM. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. NEJM 2003; 348: 1442–1448
   PubMed Web of Science ®Google Scholar
• Sills GJ, Kwan P, Butler E, de Lange ECM, van den Berg D, Brodie MJ. P-glycoprotein-mediated efflux of antiepileptic drugs: Preliminary studies in mdr1a knockout mice. Epilepsy Behav 2002; 3: 427–432
   PubMed Web of Science ®Google Scholar
• Sills GJ, Mohanraj R, Butler E, McCrindle S, Collier L, Wilson EA, Brodie MJ. Lack of association between the C3435T polymorphism in the human multidrug resistance (MDR1) gene and response to antiepileptic drug treatment. Epilepsia 2005; 46: 643–647
   PubMed Web of Science ®Google Scholar
• Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: Expression of drug resistance proteins in common causes of refractory epilepsy. Brain 2002; 125: 22–31
   PubMed Web of Science ®Google Scholar
• Tang PH, Miles MV, Glauser TA, Coletta L, Doughman N, Doose D, Frey M, DeGrauw A. An improved gas-chromatographic assay for topiramate monitoring in paediatric patients. Ther Drug Monit 2000; 22: 195–201
   PubMed Web of Science ®Google Scholar
• Tishler DM, Weinberg KI, Hinton DR, Barbaro N, Annett GM, Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 1995; 36: 1–6
   PubMed Web of Science ®Google Scholar
• Tsuji A, Tamai I. Carrier-mediated or specialized transport of drugs across the blood–brain barrier. Adv Drug Del Rev 1999; 36: 277–290
   PubMed Web of Science ®Google Scholar
• Ueda K, Okamura N, Hirai M, Tanigawara Y, Saeki T, Kioka N, Komano T, Hori R. Human P-glycoprotein transports cortisol, aldosterone and dexamethasone, but not progesterone. J Biol Chem 1992; 267: 24248–24252
   PubMed Web of Science ®Google Scholar
• Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genom Biol 2002; 3(34)1–11
   Google Scholar
• Volk H, Potschka H, Loscher W. Immunohistochemical localization of P-glycoprotein in rat brain and detection of its increased expression by seizures are sensitive to fixation and staining variables. J Histochem Cytochem 2005; 53: 517–531
   PubMed Web of Science ®Google Scholar
• Wacher V, Salphati L, Benet L. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Del Rev 1996; 20: 99–112
   Web of Science ®Google Scholar
• Weiss J, Kerpen CJ, Lindenmaier H, Dormann SMG, Haefeli WE. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J Pharmacol Exp Ther 2003; 307: 262–267
   PubMed Web of Science ®Google Scholar